23 results about "Inflammatory genes" patented technology

The invention belongs to the technical field of biology, and discloses application of wogonin in resisting siniperca chuatsi and frog iridovirus, the wogonin can effectively inhibit over-generation of ROS caused by MRV virus infection, and oxidative stress damage of host cells is relieved in a dose-dependent mode. The wogonin can be used for preventing and treating the siniperca chuatsi and frog iridovirus, the high expression state of a proinflammatory gene can be reduced, intestinal tissue damage induced by MRV infection can be relieved, proliferation of MRV in the micropterus salmoides is effectively inhibited, the MRV challenge survival rate of the micropterus salmoides is increased, a basis is provided for preparing a product for resisting the siniperca chuatsi and frog iridovirus from wogonin, and the wogonin has important application value. Meanwhile, the invention also discloses a medicine, a fish feed and a fish feed additive of the wogonin.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or anti-gen-binding portion thereof, wherein the subject is identified as having a high inflammatory gene signature score. In some embodiments, the high inflammatory gene signature score is determined by measuring the expression of a panel of inflammatory genes in a tumor sample obtained from the subject, wherein the inflammatory gene panel comprises CD274 (PD-LI), CD8A, LAG3, and STAT1.

This disclosure provides a method for treating a cancer patient comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antagonist, for example, an anti-PD-1 or anti-PD-L1 antibody, in combination with an indolamine 2,3-dioxygenase inhibitor, wherein the patient is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ-related inflammatory genes in a cancer sample obtained from the patient, wherein the gene panel comprises, for example, IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some respects, the gene panel also includes CCR5, CXCL11, GZMA, and PRF1.In some aspects, the genetic panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E and TDO2.

The invention belongs to the field of bioengineering and neurotoxicity prevention and control, and particularly relates to a neurotoxicity antagonist screening and evaluating method based on a microorganism-intestine-brain axis. The screening method of the neurotoxicity antagonist comprises the following steps: establishment of a neurotoxicity animal model, verification of the neurotoxicity model, sequencing of intestinal flora and screening of key flora, coupling analysis of flora-cranial nerve indexes, verification of candidate microorganisms, screening of core bacterial metabolites, verification of the core bacterial metabolites and verification of the core bacterial metabolites. According to the method, through behavior-neurotransmitter-inflammation-gene / mitochondrial function multi-level index linkage, a reproducible recovery index (RI) index is established, and quantitative screening and grading judgment of candidate strains and metabolites of the candidate strains on nerve injury repair are achieved.

The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.

The invention discloses prevention and treatment of diseases by stimulating TRPV1 + sensory nerves. Specifically, the invention discloses application of a substance for stimulating TRPV1 + sensory nerves in preparation of products for prevention, treatment or adjuvant treatment of inflammatory diseases, autonomic nerve dysfunction diseases or adrenal insufficiency diseases, and application of the substance for stimulating TRPV1 + sensory nerves in preparation of products for inhibiting proinflammatory cytokines and products for promoting anti-inflammatory cytokines. The TRPV1 ion channel agonist disclosed by the invention can obviously and effectively inhibit the expression of numerous proinflammatory cytokines and obviously improve the expression of anti-inflammatory cytokines IL10, so that not only is the physiological status of an inflammatory mouse obviously improved, but also the survival rate of the inflammatory mouse is obviously improved; meanwhile, the spleen function can be adjusted, expression of spleen pro-inflammatory genes is remarkably inhibited, generation of catecholamine is increased, and secretion of cortisol hormones is promoted. The invention has wide clinical application value in prevention and treatment of related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention relates to the technical field of biology, and discloses a Lactobacillus paracasei KFY202407 and an application thereof in preparation of a preparation for preventing and treating vaginitis, the collection number of the Lactobacillus paracasei KFY202407 in China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO: 30736, and the collection date is May 22, 2024. The lactobacillus paracasei KFY202407 disclosed by the invention can relieve inflammation of mice with vaginitis by regulating secretion of mouse serum inflammatory factors, activity of vaginal tissue MPO and expression conditions of vaginal tissue inflammatory genes. The microbial inoculum prepared from the lactobacillus paracasei KFY202407 has good stability and can be used as a medicine raw material.

Provided is stimulation of TRPV1+ and / or TRPA1+ sensory nerves for the prevention and treatment of diseases. Particularly provided is use of a substance for stimulating TRPV1+ and / or TRPA1+ sensory nerves in the prevention or treatment of inflammatory diseases, dysautonomia, or adrenal insufficiency, and in inhibiting the generation of pro-inflammatory cytokines and promoting the generation of anti-inflammatory cytokines. A TRPV1 and / or TRPA1 ion channel agonist can significantly effectively inhibit the expression of numerous pro-inflammatory cytokines and significantly improve the expression of the anti-inflammatory cytokine IL10, significantly improving both the physiological state and the survival rate of mice with inflammation. Moreover, the agonist can adjust spleen function, significantly inhibit the expression of pro-inflammatory genes in the spleen, increase the generation of catecholamine, and promote the secretion of cortisol-like hormones. The agonist has wide clinical application value for the prevention and treatment of related diseases.

The invention discloses application of a known compound, namely a thiazole carboxamide derivative (with the CAS number of 933886-42-1), in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome, the compound is an SLC39A1 agonist, zinc ions entering cells can be effectively increased, and by reducing the expression quantity of lung tissue inflammation genes IL-1beta and TNF-alpha of mice, the lung tissue inflammation genes IL-1beta and TNF-alpha can be effectively inhibited, so that the acute lung injury / acute respiratory distress syndrome can be effectively inhibited, and the acute lung injury / acute respiratory distress syndrome can be effectively inhibited. Therefore, lung cell infiltration in ALI / ARDS mice is reduced, oxidative damage and tissue damage of lung tissue, inflammatory factor expression and cell connection are improved, and a new choice is provided for treatment of ALI / ARDS.

The invention designs a preparation method of an active medicinal and edible composite nutrient, and the method comprises the following steps: carrying out initial culture on a ganoderma lucidum monoclonal isolate through a potato dextrose agar plate, and then transferring the ganoderma lucidum monoclonal isolate to a specific liquid culture medium for shake culture; after detecting that the activity of beta-glucosidase reaches 100 mU / mL, centrifuging to take supernatant, and adding rhizoma polygonati, lucid ganoderma and mulberry leaf powder for biotransformation; and inoculating lactobacillus plantarum, adding a freeze-drying protective additive, freeze-drying, and sieving to obtain the active medicinal and edible composite nutrient. According to the method, macromolecular active components of lucid ganoderma, rhizoma polygonati and folium mori are decomposed into small molecules through biotransformation, the problem that a traditional material is poor in intestinal absorption is solved, the prepared active medicinal and edible composite nutrient can restore the number of neutrophils, macrophages and T cells, meanwhile, tnf-alpha, il-12a and ifn-gamma proinflammatory gene expression is up-regulated, and the effect of improving the intestinal absorption rate is achieved. In addition, the natural source is high in safety, and can be used for an immune function regulation scene.

The invention discloses application of spermidine in preparation of a medicine for treating liver injury caused by iron overload, and belongs to the technical field of biological medicine. Experimental verification shows that spermidine can be applied to relieving liver iron ion deposition caused by iron dextran, reducing MDA content, effectively improving liver SOD and CAT enzyme activity and total oxidation resistance, and effectively solving the problems of liver oxidative damage and liver inflammation gene expression up-regulation caused by iron overload. Therefore, spermidine can be developed into a medicine for preventing and treating liver oxidative injury caused by iron overload. The invention finds a new effective substance for prevention and treatment of iron overload.

This invention provides a method for preparing and applying a tea polyphenol-crosslinked decellularized diaphragmatic tendon. The tendon is formed by decellularizing porcine diaphragmatic tendon with 1% TNBP and then crosslinking it with tea polyphenols. The tea polyphenol-crosslinked decellularized diaphragmatic tendon can downregulate the expression of apoptosis and inflammatory genes and upregulate the expression of antioxidant genes, exhibiting strong antioxidant properties, mechanical properties, anti-enzymatic properties, and low immunogenicity. It can enhance the antioxidant capacity of cardiomyocytes, promote myocardial tissue vascularization and inhibit fibrosis, inhibit ventricular dilation, improve fibrosis, and promote angiogenesis. It can be used in the preparation of patches for treating myocardial infarction. The tea polyphenol-crosslinked decellularized diaphragmatic tendon provided by this invention has promising applications in the treatment of myocardial infarction.

The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind Aβ peptide and 3-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of Aβ through the blood-brain barrier (BBB), oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer's disease are thought to contribute to the cause of this disorder. Embodiments of the invention use the RAGE multi-ligand site as an anchoring loci for a conversion electron emitting compound rather than as a receptor to intrinsically activate or block inflammation through the RAGE intracellular cascade through activation of the RAGE cytoplasmic tail (ctRAGE) and mammalian diaphanous 1 (DIAPH1).

The embodiment of the invention discloses a modeling method of a periodontitis and preeclampsia combined model, which comprises the following steps of: performing first-stage periodontitis modeling on an experimental mouse through continuous orthodontic ligation for 10 days, and performing continuous annular ligation for 10 days on the basis to perform second-stage periodontitis modeling on the experimental mouse, when the expression level of the inflammation gene of the gingival tissue of the experimental mouse is obviously increased, the periodontitis model of the experimental mouse is successfully established. The method comprises the following steps of: performing preeclampsia modeling on the basis of experimental mice of which periodontitis models are successfully established, randomly dividing pregnant female experimental mice into a model group and a control group, and injecting a nitric oxide synthase inhibition solution into the experimental mice in the model group, when the tail artery systolic pressure of the experimental mice in the model group is increased by at least 20mmHg compared with that of the control group and is continuously increased until the end of pregnancy, the periodontitis and preeclampsia combined model of the experimental mice is successfully established, and the model has important academic value and clinical significance for reducing the occurrence rate of complications in the gestation period and improving maternal and fetal prognosis.

The invention belongs to the field of new application of medicines, and particularly relates to application of retinaldehyde in preparation of medicines for treating Toll-like receptor mediated inflammation and the medicines. It is found for the first time that retinaldehyde can be used for inhibiting TLR-mediated inflammatory reaction through targeted activation of OPN3, experimental results show that after all-type retinaldehyde and 9-cis-retinaldehyde are treated, the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes in human mononuclear macrophages stimulated by PAM3CSK4, VTX-2337, TNF, Agatolimod and Poly (I: C) can be remarkably reduced, transcriptome experimental data show that the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes in the human mononuclear macrophages can be remarkably reduced, and the expression quantity of TNF, IL6, IL18, IFNB1 and ISG15 inflammatory genes can be remarkably The all-form retinaldehyde and the 9-cis-retinaldehyde can activate OPN3 and are used for inhibiting TLR-mediated inflammatory reaction, so that a new thought is provided for treatment of inflammation, and the pharmaceutical application of the retinaldehyde is expanded.

The invention discloses an ovarian cancer prognosis analysis method, system and device, and the method comprises the following steps: 1, obtaining case data of an ovarian cancer patient, and removing case data without patient survival information, the case data comprising patient clinical data and ovarian cancer gene expression data; 2, carrying out clustering analysis on the gene expression data and inflammation genes of the ovarian cancer patients meeting the requirements in the step 1, and screening out differentially expressed inflammation related genes; 3, performing univariate Cox regression analysis on the differential gene expression level obtained in the step 2 and the survival rate of the ovarian cancer patient, and screening inflammation-related genes with prognosis value; through multivariable Cox regression analysis, inflammation-related genes with remarkable ovarian cancer prognosis are screened; 4, establishing an ovarian cancer prognosis model based on the ovarian cancer prognosis significant inflammation related genes screened in the step 3; and 5, based on the prognosis model constructed in the step 4, performing prognosis analysis on the case data of the ovarian cancer patient. Through verification, the prognosis model constructed by the invention can be used for prognosis of ovarian cancer patients.

The invention provides a repairing and soothing composition and application thereof. The composition comprises fibronectin, a centella asiatica extract, allantoin, tetrahydromethylpyrimidine carboxylic acid and xylitol glucoside. It is creatively found that the centella asiatica extract, allantoin, tetrahydromethylpyrimidine carboxylic acid and xylitol glucoside can synergistically improve the biological activity of fibronectin, the highly active state of cells is kept in the skin absorption process, and fibronectin forms a stable framework between the cells; by inhibiting the expression quantity of the TNF-alpha inflammatory gene, the excellent repairing and relieving effects are achieved; on the basis of repairing the skin barrier, the tyrosine protease activity is further inhibited, and the skin is whitened and brightened.

The application belongs to the technical field of active ingredient extraction, and particularly relates to a citrus extract, a preparation method and application thereof. The citrus extract provided by the application can reduce the pain sensitivity of oral ulcer, reduce the ulcer area, and reduce the inflammatory expression of oral ulcer due to the reasons such as reducing the expression of inflammatory genes and proteins and reducing the accumulation of inflammatory factors.

The application provides a combination of an EphA2-specific tyrosine kinase inhibitor and a statin and application thereof, and belongs to the technical field of pharmacy.The application proves that the statin can up-regulate the expression of EphA2 in macrophages at the cell and mouse levels.The EphA2-specific tyrosine kinase inhibitor ALW-II-41-27 can significantly inhibit the expression of inflammatory genes and proteins such as Nlrp3, IL-1beta and TNF-alpha of macrophages induced by the statin, and can also remodel intestinal flora, regulate the metabolic pathway of the flora, promote the generation of secondary bile acids with anti-inflammatory effect, and further prove that the combination of ALW-II-41-27 and the statin can reduce the atherosclerotic plaques of mice and increase the stability of the plaques.ALT-II-41-27 can block the pro-inflammatory effect of the statin on macrophages, and has a broad prospect in the aspect of anti-atherosclerotic combination therapy drugs.

The application belongs to the technical field of new application of medicines, and particularly relates to hydroxycinnamic acid derivatives, a preparation method and application thereof. The ARDS model is induced by LPS tracheal instillation combined with hydroxycinnamic acid derivatives, the alveolar lavage fluid cell count is determined, and the pathological characteristics and the expression level of inflammatory genes of lung tissues are detected; the results show that the hydroxycinnamic acid derivatives can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce the expression level of inflammatory factors.

The invention belongs to the field of stem cell genetic engineering, and provides application of NLRP12 in anti-inflammatory osteogenesis promotion of periodontal ligament stem cells. According to the NLRP12 overexpression PDLSCs, the anti-inflammatory gene is applied to periodontal regeneration treatment, and the anti-inflammatory capacity and the tissue defect repairing capacity after the PDLSCs are transplanted into a body are effectively improved. An exogenous gene is transferred into PDLSCs through a virus vector, stable transfection and efficient and continuous expression of an anti-inflammatory gene are achieved, and the repair effect of periodontitis tissue defects is promoted. In-vitro experiments show that NLRP12 overexpression in an inflammatory microenvironment alleviates the inflammatory response and osteogenic differentiation inhibition of PDLSCs, which shows that the expression of proinflammatory factors IL-6 and IL-8 is down-regulated, the expression levels of anti-inflammatory factors IL-10 and osteogenic related proteins RUNX2, COL1 and BMP2 are up-regulated, ALP dyeing and alizarin red dyeing are deepened, and mineralized nodule formation is increased. The NLRP12 overexpression PDLSCs is applied to a rat experimental periodontitis model in vivo, inflammatory reaction is remarkably relieved, and periodontal tissue regeneration of periodontitis rats is promoted. Mechanism research shows that the NLRP12 alleviates the inflammatory response of PDLSCs and osteogenic differentiation inhibition by inhibiting an NF-kappa B pathway. The NLRP12 overexpression PDLSCs are suitable for repairing periodontal tissue defects, and have a good clinical application prospect.

The application belongs to the technical field of safflower and specifically relates to a safflower extract and a preparation method and application thereof, and the safflower extract is obtained by alcohol extraction of safflower kernel skin, and the content of phenylacryl-5-hydroxytryptamine compounds in the extract is 45%-55%. The content of PAHA in the safflower kernel skin extract provided in the application reaches 50%, SKE has good antioxidant activity, can effectively scavenge free radicals and thus delay the oxidation process; the overall antioxidant capacity of HEK293T cells treated by SKE increases, the ability of scavenging free radicals and scavenging peroxides in the body can be enhanced; SKE can effectively slow down the expression increase of inflammatory genes IL-1alpha, IL-6 and COX2 caused by E. coli; SKE has a significant inhibitory effect on specific growth stages of E. coli and Staphylococcus aureus.